HWGB WILL BENEFIT ENORMOUSLY FROM EBI'S RECENT “PHASE IV” CLINICAL TRIAL.
THIS HAS PLACED EBI AHEAD OF ITS COMPETITORS WHICH ARE NOW AT “PHASE III” ONLY.

On 13th Sept 2020, EBI has engaged the services of Roderick A. Comunale II MD Inc (Principal Investigator) to conduct a clinical research study entitled “Inactivated Polio Vaccine in prevention of COVID-19 in high risk population in a Phase IV study, which shall study the effects of Inactive Polio Vaccine-IPV which shall be conducted according to the US Food and Drug Administration approved protocol and to be provided by EBI.

1) COVID-19 VACCINE TRACKER
Globally, researchers are testing 40 vaccines in clinical trials on humans, and at least 92 preclinical vaccines are under active investigation in animals.

China is conducting clinical trials of 11 COVID-19 vaccines, 4 of which have entered Phase III trials, said Wang Zhigang, Chinese minister of Science and Technology, at the Global Science and Life Health Forum in Beijing on Friday (18th Sept 2020).

2) UNDERSTANDING THE 5 PHASES OF CLINICAL TRIALS
https://en.m.wikipedia.org/wiki/Clinical_trial#Phases
Clinical trials involving new drugs are commonly classified into five phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug development process will normally proceed through phases I to IV over many years, frequently involving a decade or longer. If the drug successfully passes through phases I, II, and III, it will usually be approved by the national regulatory authority for use in the general population.

Phase IV trials are performed after the newly approved drug, diagnostic or device is marketed, providing assessment about risks, benefits, or best uses. ---> This refers to EBI’s Phase IV study;

3) UNDERTANDING THE TECHNICAL ROUTE FOR VACCINE DEVELOPMENT
Vaccine development usually adopts five technical routes worldwide, namely inactivated vaccines, recombinant protein vaccines, attenuated influenza virus vaccines, adenoviral vector vaccines, and nucleic acid vaccines (mRNA, DNA).

(i) The inactivated vaccine is the most common approach. Its features are simple, rapid development, high safety, and usually used to deal with acute diseases. ---> This refers to EBI’s “Inactivated Polio Vaccine in prevention of COVID-19 in high risk population in a Phase IV study;

(ii) Adenovirus vector vaccine is made by using harmless modified adenovirus as a carrier and loaded into the virus' spike protein gene to stimulate the production of antibodies in the human body. It is safe, efficient, and causes few adverse reactions.

4) CONCLUSION
On 9th Sept 2020, Bursa announced that HWGB BIOTECH SDB BHD had earmarked its production facilities by appointing XKX as a non-exclusive manufacture to produce vaccine.

XKX has the production facilities and is able to manufacture poliomyelitis vaccines, including different strains and formulation and dosage form systems of oral poliovirus (OPV), Oral Poliovirus (liquid) (OPVL) and Inactivated Poliovirus Vaccine (IPV) (“Polio Vaccines”) and the new indication which proposes the use of existing Polio Vaccines for prevention of COVID-19 virus (collectively “Vaccines”).

This was the last piece of the jigsaw puzzle to complete HWGB Biotech Sdn Bhd’s production & sales setup for EBI’s vaccine.

Should one invest in this vaccine production company now?
You’ll be your own judge!

[DISCLAIMER – TAYOR]
© ATH
https://ibb.co/n0tLMjj

Was this announcement timed for a LU on Monday???
https://ibb.co/pLrYZgy

Technically, gloves stocks have entered into a bear trend.
Funds will switch over to vaccines' counters.

Over the course of the year, HWGB has made a slew of announcements following ventures into the Covid-19 related business that had been announced by the group earlier that range from test kits to clinical trials for vaccines.

1) In May, HWGB said its unit HWG Consortium Sdn Bhd (HWGC) had been appointed the authorised distributor of Shanghai Liangrun Biomedicine Technology Co Ltd for the distribution of its antibody IgM/IgG of novel coronavirus Covid-19 diagnostic kit in Malaysia for a validity period from May 15 to Dec 31.

It said HWGC had also submitted an application to the Ministry of Health (MoH) for the certification of the diagnostic kit, pending approval.

COMMENT - The duration needed to obtain MOH's approval for the test kits averaged about 3 to 4 months. The outcome should be known anytime now.

2) On June 3, the group’s unit HWGB Biotech Sdn Bhd received an authorisation letter from Sansure Biotech Inc to be Sansure’s general distributor to promote and publicise its Covid-19 nucleic acid detection kits and instruments in Malaysia.

3) On June 19, it entered into a product purchase agreement with Zhejiang Plame Medical Technology Co Ltd, a company duly authorised by Shanghai Liangrun to handle matters relating to its diagnostic kit in Malaysia.

4) On June 26, it said its unit HWGB Biotech had entered into a memorandum of understanding (MoU) with Gnosis Laboratories (M) Sdn Bhd.

5) These culminated in its latest filing last Thursday, when HWGB said HWGB Biotech had partnered with US-based E-MO Biology Inc (EBI) for HWGB to invest a sum of US$1 million (RM4.2 million) in EBI, entitling it to 40% of profit from the commercialised vaccine.

HWGB said it will have exclusive rights for the production, distribution and sale of the repurposed vaccine based on the polio vaccine for use in preventing Covid-19 infections in Southeast Asian countries.

“EBI on June 15 submitted the Initial Investigational New Drug application to the United States Food and Drug Administration to conduct phase IV clinical trials for a new indication which proposes the use of the existing poliomyelitis virus vaccine for prevention of Covid-19, which is currently pending approval;

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3086706

Announcement
Description RESEARCH PROTOCOL ON THE EFFECTIVENESS OF ORAL POLIO VACCINE (OPV) AS A PREVENTIVE PROTECTION AGAINST THE SARS-COV-2 VIRUS
The Board of Directors of Ho Wah Genting Berhad wishes to announce that its wholly owned subsidiary, HWGB Biotech Sdn Bhd (Formerly known as HWG Consortium Sdn Bhd) (“HWGB Biotech”), had on 7 September 2020 submitted a research protocol (with Research ID 56372) to National Medical Research Register (“NMRR”) under The Ministry of Health, Malaysia (“MOH”) to evaluate the effectiveness of OPV as a preventive protection against the SARS-CoV-2 virus (“Research Protocol”). The Research Protocol will be fully funded by HWGB Biotech who will hold the full rights on the clinical trial and other related matters.

Please refer to the attach file for the details of the announcement.
This announcement is dated 7 September 2020.

Following K1's nod from MDA to supply nasal swaps, HWGB should be next in getting the approval for its rapid test kits & nasal swaps anytime from now!

You can't get any better than this!!

Msg from a Bursa friend: -

"Hi Broker partners, it has come to my attention that this email is circulating through whatsapp and has creating noise. I would like to clarify that Bursa *Have Not* and *Do Not* send out any precautionary advise on this matter. Please advise your salesforce and your network accordingly."

https://ibb.co/WDRtdnd
From PM Securities

Gogogo...
UG healthcare, another listed glove maker in Sgx. It have similar business model with OBM + distributir, but have much smaller capacity if compared to supermax. UG price have surge more than 32% today!!!

Of late, so much hype has been given to the glove counters due to the massive hike in its ASP. In view of the imminent threat of a 2nd wave Covid-19 infection across the globe, its time to refocus on the next big demand, ie the VITAL Ventilators developed by NASA Jet Propulsion Laboratory whereby K1 will be one of the biggest beneficiary.

Perhaps it would be more productive to guesstimate how much is the profit margin to K1 in producing this low-cost ventilator for this quarter. Here are some of the clues obtained on the cost of production: -

1) USA - Btwn US$2k to US$3K (RM9K to RM13K)
"Though officials did not offer an exact cost for producing the ventilator, Gallagher estimated that it would be roughly US$2,000 to US$3,000. For comparison, General Motors is producing low-cost, conventional ventilators for the national stockpile at more than US$16,000 apiece."
https://www.businessinsider.com/nasa-designs-cheap-simple-coronavirus-ventilator-mass-production-2020-4

2) SINGAPORE - Btwn SGD7K to SGD9K (RM21K to RM27K)
"Costing between S$7,000 and S$9,000, the SG-Inspire is five times cheaper than a conventional ventilator. As it uses readily available components, the ventilator can be mass-produced quickly, within a month, complementing the conventional ventilators should the need arise."
https://www.straitstimes.com/singapore/singhealth-team-develops-ventilator-to-pre-empt-shortage-for-severe-covid-19-cases

3) COST TO PRODUCE A TYPICAL VENTILATOR: - Average around US$30K (RM127K)!
https://www.cnbc.com/2020/05/30/nasa-other-innovators-redesign-ventilators-for-coronavirus-patients.html

*For a patient in true ventilatory failure, a ventilator is really the only solution.

Insiders are buying...good sign :)

RM1.00 coming!

Volume has kicked in >50m!
Breakout of 0.45 already. Bullish Belt Hold Line forming nicely;
No stopping K1 from today till Friday!

This is getting surreal..."as many as 1 in 150 people in U.S. are infected with coronavirus".
https://www.cnbc.com/2020/07/10/dr-scott-gottlieb-on-coronavirus-infection-levels-in-the-us.html

Tremendous earnings' growth going forward...
“We expect the cloud business to take up an increasing portion of K-One’s total revenue and earnings when it spreads its wings to the Asean region, with rising contributions from the region in the next few years. As for 2020, we forecast that the cloud business will represent a significant portion of K-One’s total business.”

Xendity's purchase will attract more Singaporean funds to come in.
Digitalisation is the in-thing now and every investor would like to own a piece of it. At SGD0.23 (RM0.70), its considered very attractive to them.
This is just the beginning for GPacket!

Ho Wah Genting to raise RM31.5 million via issue of ICPS
In a filing today, loss-making HWG announced that part of the money raised is meant for its healthcare related business which is its latest venture to jump onto the pandemic bandwagon.
https://www.theedgemarkets.com/article/ho-wah-genting-raise-rm315-million-issue-icps?type=malaysia

Its all system goes for HWGB's transformation to the healthcare sector!

CHANGE OF NAME OF SUBSIDIARY COMPANY
The Board of Directors is pleased to announce that the following subsidiary company had changed its name with effect from 5 June 2020 being the date of the Notice of Incorporation on Change of Name of Company (Section 28 of Companies Act, 2016) issued by Companies Commission of Malaysia:

Old Name - Rex Oriental Sdn Bhd
New Name - DVIRIA NANO TECH SDN BHD. (Company No: 201301027003 (1056831-K)
https://m.malaysiastock.biz/Company-Announcement.aspx?id=1233117

It will fly...patience...

Expected cost and benefits of the Sansure Authorisation

The cost required for the Sansure Authorisation is estimated to be up to RM2 million, which will be funded via internally generated funds or borrowings. Subject to the approval by MDA, the Sansure Authorisation is expected to "contribute positively to the future financial performance of the Group."

BREAKING NEWS - Why SANSURE BIOTECH INC'sNovel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing) will be a big hit?
1) This is because Sansure Biotech Inc's daignostic kit uses "Nasal Swab Test". It's not a rapid test kit that uses blood test type like those manufactured by Shanghai Liangrun. Please note the differences!
2) is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal (throat) swabs, anterior nasal swabs, mid-turbinate swabs, nasal washes and nasal aspirates from individuals who are suspected of COVID-19 by their healthcare provider.
http://eng.sansure.com.cn/index.php?g=&m=article&a=index&id=81

NEWS HEADLINE - "Ismail Sabri: Govt to allow Malaysians working in Singapore to travel back and forth, with swab tests taken, after bilateral negotiations."
Read Ismail Sabri's lips again "swab tests". Does this ring a bell gentlemen??
https://www.theedgemarkets.com/article/ismail-sabri-govt-allow-malaysians-working-singapore-travel-back-and-forth-swab-tests-taken?type=malaysia

Did you know that some 300,000 Malaysians work in Singapore? It is believed that about half of them cross the border with Singapore every day?
https://www.unscrambled.sg/2020/03/17/over-100k-malaysians-cross-the-border-to-work-in-singapore-every-day-what-if-theyre-in-essential-services/

Obviously the Government must have already planned to outsource the nasal swap test kits from an appointed distributor to cater for this new increased in demand. In this aspect, who else but HWGB could be one of the biggest beneficiary!
https://m.malaysiastock.biz/Company-Announcement.aspx?id=1231653

Moving forward, due to the expected increase in earnings, the TP has been revised upwards from 1.00 to 1.50;
P/S: - Wishing all the Smart Sorchais who has bght goodluck! :-)

The kits, developed by Sansure Biotech, a Changsha-based biotech company, can shorten detection time and recognize suspected cases, especially latent infections.

Helped by an automatic nucleic acid extractor and a mobile molecular diagnostic platform developed by Sansure Biotech, the kits can generate test results in 30 minutes.
http://www.xinhuanet.com/english/2020-01/30/c_138742202.htm

Game changer for GP finally - "Green Packet's Kiplepay awarded Visa principal issuing licence, joins Visa Fintech Fast Track programme!"

This timely announcement of its distributorship for the Covid-19 nucleic acid detection kits & instruments in M'sia will be the catalyst needed to break 0.60 :-)

Three positive takes: -
1) The Price Capping set by Malacca Securities has infact been lowered from 50% to 40% only w.e.f. tmrw, 4/6/20;
2) K1 has not hit any limit-up as yet so its price is still relatively cheap as opposed to those bloated glove stocks. Meaning to say, anything below 1.00 would still be considered as attractive!
3) Now that K1 has stated their work plan regarding the NASA-JPL's VITAL Ventilators to Bursa, more institutional & retailers would want to own a piece of this company's lucrative shares. And so long as demand outbids supply, its price will continue to soar irrespective of whether the cap has been enforced. Never underestimate the buying power of the small retail investors using cash!

Malaysia, Singapore to resume discussions on high-speed rail project soon — Azmin
https://www.theedgemarkets.com/article/malaysia-singapore-resume-discussions-highspeed-rail-project-soon-%E2%80%94-azmin

Chances are that it may revert back to its original plan signed under ex-BN govt...bigger budget, more stations, faster speed...nice :-)

Extremely good set of quarterly results!
QoQ +122.99%
YoY +215.74%
https://klse.i3investor.com/servlets/stk/fin/9601.jsp
Might hit limitup tmrw!

GREEN PACKET KIPLELIVE SALES SOAR

"With such high demand for KipleLive, Ti is optimistic that his division will achieve its target of sales revenue hitting RM60m by Q3 of this year. This will be a boost to the overall earnings of Green Packet this year."

Today, Riverstone is up 14% and Topglov is up 13% in SGX.
Comfort, Supermx and Carepls will fly in Bursa tomorrow.
Goodluck!

POST VIRUS RALLY

"Senior Minister for International Trade & Industry Azmin Ali, has said that the government will announce a 6-month short term recovery plan by the end of May 2020. After which, a medium-term revitalisation plan under Budget 2021 will be tabled in November 2020.

Maybe its a slow week for news, but TheEdge had another article in the May 25-31 edition, saying that the HSR may cost RM68bn.

At the end of the day, the top beneficiaries will be Ekovest and IW City.

You will notice from both charts of IW City and Ekovest that they were readying to surge a few days back but were caught up in the massive profit taking after 3 straight days of huge volume activity. From the above analysis, it is highly likely that both will resume its uptrend. Initial target levels of 80 sen and 70 sen for IW City and Ekovest look like attainable."

http://malaysiafinance.blogspot.com/2020/05/post-virus-rally.html?m=1

With the current situation of COVID-19, reaching a potential second wave internationally, testing requirements are expected to balloon in the coming months.

While the Government has actively sought to provide adequate testing facilities and resources to the general public, there has to be increased contribution from the private sector, if the economy is to be returned to normalcy as soon as possible. This is where the demand for HWGB's premium Shanghai Liangrun test kits will boom!

Selamat Hari Raya & see you at 0.50 next week :-)

HWGB: HEALTH & WEALTH = GOOD BLESSINGS
A TURNAROUND STORY IN THE MAKING

#Posted by Spectre888 > May 17, 2020 9:13 PM | Report Abuse

How much profits would HWGB be generating from the sale of the Shanghai Liangrun's rapid test kits?

(i) With our population of abt 32m, let's assume 20% as the population that will be tested over the next 6 months. That is about 6.4m people (excluding PRs, Work Permit holders, tourists, illegal immigrants, etc);

(ii) Based on the on-going market rate of RM380 for a drive through or walk-in client, a total revenue of abt RM2.4B revenue is expected to be collected over the next 6mths;
https://my.healtopedia.com/product-category/services-packages/covid-19-test-1/?gclid=CjwKCAjwwYP2BRBGEiwAkoBpAuddLjCWk7h1vsV1aUdrfWWiKgDqygeFTDGAenQZkbbAggJ7Jete-RoClUsQAvD_BwE

(iii) As there are 5 rapid test kits recommended by the MOH, namely Lionrun Shanghai Liangrun Diagnostics Kit, Wondfo, Vazyme, Standard Q Covid-19 igM/IgG Combo, and Healgen, the market share of the total revenue that is expected to be earned by HWGB = (20% of RM2.4B) = RM480M.

(iv) Let's assumed that the profit margin for HWGB is 35%. This will translate into (35% of RM480M) = *RM168M over 6 months (or RM28M per month);
* This is only a rough & conservative estimation. Imagine the added potential to be reaped from the appointed sub-distributor, PM Care Sdn Bhd with its network of more than 3,500 medical providers nationwide!

Folks, we all know that a vaccine for Covid-19 can only be found some 1.5yrs or more down the road. Figures don't lie, so its no wonder that this attractive profit margin is freaking out the Board who has been frantically trying to takeover the company with their cheapo offer price of 0.125, 0.14 & 0.205 respectively!! Expect smart investors to come in and stop them in their tracks tomorrow!!!

HWGB is certainly on a roll for now! Goodluck :)

HWGB: - "HEALTH & WEALTH = GOOD BLESSINGS!"
Congrats to those who bought earlier.

Gloves demand aside, many investors have neglected the fact that Rapid Test Kits will be the most vital medical equipment that is needed by frontline workers to identify positive Covid-19 patients. One may be fully masked & equipped with gloves but that will not be able to detect the presence of Covid-19.

In view of this, HWGB has scored a major breakthrough in their diversification into the healthcare sector with this new product. Going forward, the prospective future earnings is very bright as can be seen by the figures illustrated by Spectre888, that is self explanatory.

Among the 5 test kits that were approved by MOH, the one from Shanghai Liangrun ranked first in the evaluation of the new crown antibody detection. That speaks volume for itself on the reliability of this product from China. Thus, it will definitely be the preferred choice among medcal practitioners.

Until Covid 19 is under control the demand for Rapid Test Kits will be very high. HWGB's earnings will increase and it will be reflected on their share prices ultimately when more & more investors & retailers see its potential. Buy before it breakout from 0.38!

SHANGHAI LIANGRUN'S NEW CROWN IgM / IGG TEST FOR COVID-19 HAS ALREADY ASSIGNED THE FOLLOWING DISTRIBUTORS WORLDWIDE: -

A) TODO MEDICAL LTD - https://www.globenewswire.com/fr/news-release/2020/03/30/2008409/0/en/Todos-Medical-Expands-on-Coronavirus-COVID-19-Distribution-Agreement-with-Shanghai-Liangrun-Subsidiary-Gibraltar.html
B) VEREDUS LABORATORIES PTE LTD (SINGAPORE) - https://ibb.co/cNssQbd
C) HWGB (MALAYSIA) - https://ibb.co/vv191cP

HWGB must have been distributing discreetly to MOH since end-April 2020. Hence, they already knew in advance the lucrativeness involved in this business!

MOH Sends Socso Covid-19 Testing SOP For Workers
"As for the antibody test, also known as serology tests, MOH recommended the usage of serology rapid test kits (RTK) that are validated by Institute of Medical Research (IMR) or the National Public Health Laboratory (NPHL). The rapid antibody tests recommended are Lionrun Shanghai Liangrun Diagnostics Kit, Wondfo, Vazyme, Standard Q Covid-19 igM/IgG Combo, and Healgen."
https://codeblue.galencentre.org/2020/04/24/moh-sends-socso-covid-19-testing-sop-for-workers/

HWGB denotes "HEALTH=WEALTH=GOOD BLESSINGS" :)
ITS ALL SYSTEM GO AS THE SHANGHAI LAINGRUN DIAGNOSTIC KIT FOR COVID-19 HAS BEEN APPROVED BY THE MOH
https://ibb.co/ry8XbTQ

Points To Ponder Over: -
1) ON 3/4/20, THE COVID-19 TEST KIT ANNOUNCED BY BURSA WAS FROM THE MANUFACTURER, WUHAN EASYDIAGNOSIS BIOMEDICAL CO LTD. AS SUCH, IT CAME AS A SURPRISED WHEN A DIFFERENT MANUFACTURER BY THE NAME OF SHANGHAI LIANGRUN BIOMEDICINE TECHNOLOGY CO LTD WAS ANNOUNCED BY BURSA ON 15/5/20 FOR ANOTHER DIAGNOSTIC KIT FOR COVID-19;

2) THAT MEANS, INSIDERS ALREADY KNEW ABOUT THE APPROVAL GRANTED BY THE MOH ON 27/4/20 FOR THIS DIAGNOSTIC KIT FOR COVID-19 MANUFACTURED BY SHANGHAI LIANGRUN ;

3) NOW, WHY WEREN'T THIS PIECE OF VITAL INFORMATION REVEALED BY HWGB TO BURSA IMMEDIATELY? INSTEAD, IT WAS DELIBERATELY WITHHELD UNTIL 15/5/20? EVEN THEN, THE ANNOUNCEMENT MADE WAS NOT OUTRIGHT AS IT STATED THAT "HWGC HAD ALSO SUBMITTED AN APPLICATION TO THE MOH" WHEN INSIDERS KNEW VERY WELL THAT THE APPROVAL WAS ALREADY GRANTED BY THE MOH ON 27/4/20!

4) TO RECAP, 27/4/20 ALSO HAPPENED TO BE THE DATE THAT THE TAKEOVER OFFER PRICE OF 0.125 WAS FIRST ANNOUNCED BY BURSA. SUBSEQUENTLY, THE OFFER PRICE WAS REVISED UPWARDS FROM 0.14 TO 0.205. AGAIN, WAS THIS COINCIDENTAL OR WAS IT A METICULOUSLY PLOT EXECUTED WITH SOME MALICIOUS INTENT TO UNDERMINE THE PRICE SO AS TO BENEFIT CERTAIN PARTIES??? GO FIGURE IT OUT YOURSELF GUYS!

*Congrats to those brave hearts who are still holding tight to their shares. May all of you be blessed abundantly!
With the MOH's approval already granted, the price should rally and hit limit up @ 0.59 come Monday. This is another Carepls & GPacket in the making :)))

Ho Wah Genting to distribute China-developed Covid-19 diagnostic kit in Malaysia
https://www.theedgemarkets.com/article/ho-wah-genting-distribute-chinadeveloped-covid19-diagnostic-kit-malaysia

@Funny - Its all legally penned. U can scroll back from here to check..
https://m.malaysiastock.biz/Bursa-Announcement.aspx?code=9601&cat=9&page=1

A hidden gem know only to the Directors who are scheming to takeover the company but don't let it go for cheap. Hang on tight!

HWGB is in the transitional process of migrating to the healthcare sector.
Till-date, HWGB has roped in 4 exclusive health products to combat the Covid-19 virus, namely: -

1) Covid-19 Test Kits and

2) Nucleic Acid Extraction Reagent - from Wuhan Easydiagnosis Biomedicine Co Ltd;
http://www.mdeasydiagnosis.com/en/products/Molecular/2020-03-20/63.html
http://www.mdeasydiagnosis.com/en/products/Molecular/2020-03-20/64.html

3) acuMMUNE Capsules - from Guardion Healyh Sciences Inc;
https://www.globenewswire.com/news-release/2020/04/14/2015815/0/en/Guardion-Health-Sciences-Announces-Launch-of-acuMMUNE-An-Immuno-Supportive-Anti-Oxidant-Complex.html

4) Lianhua Qingwen Capsules - from Shijiazhuang Yiling Pharmaceutical Co Ltd;
https://www.prnewswire.com/in/news-releases/lianhua-qingwen-capsule-granule-was-approved-as-an-additional-indication-of-covid-19-890622097.html

These 4 prime heathcare products are certainly the main reason behind the Board's intent to takeover the company at a measly offer of 0.205 sen only! Don't be fooled by them. Hold on tight to your shares now that it's definitely worth a fortune...TP=1.00 is coming! :-)))

Big funds are buying aggressively after confirming the potential future earnings derived from: -
1) Contactless Thermal Scanners; and
2) Agreement with Tencent to provide e-KYC (Electronic Know Your Customer) services;
This is a hidden blue chip in the making!!!

Besides gloves, not many are aware that contactless thermal scanners will be the next big thing. Take the cue from China & Singapore....

1) CHINA - China’s largest maker of thermal imaging equipment has sold thousands of fever screening systems in the past two weeks as authorities and businesses rush to deploy them at airports, railway stations and other public gathering places, sales manager Thomas Chen says via email. Typically, the company typically only sells about 100 a year.

“We don’t even have a break for Chinese New Year,” says Chen. “Now we are running as fast as we can.”

The Chinese military, one of its biggest customers, has to wait — the company has halted production of night vision scopes and other products to free up capacity to churn out its fever detection systems, which range in price from $5,000 to $30,000.

2) SINGAPORE - “The demand at this moment is unprecedented,” says Leonard Lim, founder and CEO of Singapore-based Omnisense. “If you try to call our office now you probably won’t get through, the lines are jammed.”

3) MALAYSIA - GPacket will be the leader to cater for the strong demand locally. Grab some before its price shoots up like Comfort & Ruberex :-)))

https://www.forbes.com/sites/jeremybogaisky/2020/02/10/we-are-running-as-fast-as-we-can-coronavirus-sparks-surge-in-demand-for-infrared-fever-detection-equipment/#8e071d360c91

Good try Dotazeus but too bad this gimmick won't let you get to buy Ages cheap anyway...go get a life..lol

BOYIJUN RESOURCES (HK) LIMITED was incorporated on 2018-09-05 as a Private company limited by shares registered in Hong Kong. It's company registration number is: 2742155. The company is Live now.

Company Name:BOYIJUN RESOURCES (HK) LIMITED
Company Name (Traditional Chinese):香港佰威駿資源有限公司
CR No.2742155
Date of Incorporation:2018-09-05
Company Type:Private company limited by shares
Company Status:Live
Remarks:-
Register of Charges:Unavailable
Name History:2018-09-05
BOYIJUN RESOURCES (HK) LIMITED
https://www.hkcompanydirectory.com/en/boyijun-resources-hk-limited-

Relax...it will move up swiftly once the feeling has sunk in.
Many are still recovering from the MCO :-)

The bar has been raised from 0.125 to 0.14.
Later on, they will have to up the stake again to 0.18...lol
https://m.malaysiastock.biz/Company-Announcement.aspx?id=1225116

INTRODUCTION TO acuMMUNE
An Immunosupportive/Anti-inflammatory Antioxidant Complex, acuMMUNE is a unique nutraceutical formulation designed to support effective immune function – including in particular interferon-mediated anti-viral mechanisms – while also helping to mitigate the excessive lung inflammation that can lead to the harsh symptoms associated with certain respiratory infections. Hence, acuMMUNE provides both immunosupportive and anti-inflammatory benefits.

The proprietary blend of the highly effective antioxidants and anti-inflammatories, combined with the most powerful antioxidant in nature, astaxanthin, creates a targeted physiological network designed to enhance an effective interferon response to many types of viruses; interferon works through multiple pathways to suppress intracellular viral replication. At the same time, these agents exert anti-inflammatory effects that can help to prevent or control the excessive lung inflammation that can make some infections deadly.

Beta-Glucan has been clinically proven to help stave off and control infections through enhancing the function of dendritic cells. These cells process antigens from infectious agents, which in turn recruit lymphocytes responsive to these antigens and create protective antibodies to eliminate virus-infected cells.

Zinc supplementation supports efficient multiplication of various immune cells, while also exerting protective anti-inflammatory effects. Several studies demonstrate that zinc supplementation can decrease infection risk in highly susceptible patients, such as young children and the elderly.
https://store.nutriguard.com/acummune

acuMMUNE: an Immunosupportive/Anti-Oxidant/Anti-Inflammatory Complex
Now Available from our subsidiary NutriGuard.

We purposefully designed acuMMUNE with you and your health in mind. acuMMUNE is a unique condition-specific nutraceutical product composed of a proprietary blend of a highly effective immunosupportive/antioxidant/anti-inflammatory complex that includes the most powerful antioxidant known in nature, Astaxanthin. Astaxanthin is 6,000 times more powerful than vitamin C. All of this to provide our customers with the most efficacious product possible to support immune health.

To receive the maximum benefit from acuMMUNE, we recommend a daily dose of 9 capsules total. This dose accommodates the volume of ingredients while keeping the capsules small enough to avoid discomfort when swallowing.

We are thrilled to provide you the support your immune system needs — with acuMMUNE!
https://guardionhealth.com/

Further readings: -
5 Reasons to Take Astaxanthin Every Day - For humans, astaxanthin is a powerful antioxidant with broad health implications, and unlike other antioxidants, such as beta carotene, zeaxanthin, vitamin E, C, D and selenium, astaxanthin never becomes pro-oxidant in the body.
https://www.google.com/amp/s/www.huffpost.com/entry/astaxanthin_b_2750910/amp

My comments: -
1) acuMUNE should be a hot seller as it targets the niche market for the affluent. Affluent consumers perceive themselves as important, valuable customers, and they expect to be recognized and treated as such at every point in the customer lifecycle. They also demand products and services that fit their lifestyle needs and live up to (or even exceed) their extremely high expectations;

2) At US$75 per kit, US$875,000 can buy abt 11,667 kits. Assuming a profit margin of (30% x US$75) per kit =US$22.50. So, (11,667 kits x US$22.50) = US$262,507.50 or RM1.13M. If Astramune Sdn Bhd can sell 50,000 kits per year, that works out to a profit margin of (50,000 x US$22.50) = US$1,125M or RM4.838M! Wow, that's quite a tidy sum indeed!

3) Pay attention to HWGB as it leans towards the health sector which is a defensive sector. You can't be wrong cos only the healthcare sector is in the GREEN :-)))

What could possibly be stirring HWGB last Friday that caused it to rebound strongly to close up 4sen at 0.21?

Besides the Covid-19 Test Kit, nothing much has been mentioned about their 5-year Manufacturing and Supply Agreement that was signed between Astramune Sdn Bhd (a wholly-owned subsidiary of HWGB) and Guardion Health Sciences, Inc (GHSI) on 30 March 2020.

1) A quick search via Google showed that Astramune Sdn Bhd had infact placed an initial order for US$875,000 (RM3,762,500) worth of AcuMMUNE from GHSI on 1/4/20: -
"--Initial order for US$875,000 from Astramune Sdn Bhd, a subsidiary of Ho Wah Genting Berhad
--Formula designed to provide immune-supportive benefits
--Formula developed by the Company’s NutriGuard business unit".
https://www.globenewswire.com/news-release/2020/04/01/2009890/0/en/Guardion-Health-Sciences-Receives-Initial-Order-from-Malaysian-Company-for-Exclusive-Immuno-Supportive-Formula.html

2) Subsequently, this initial order even created some excitement amongst the forum members in Stockwits; https://stocktwits.com/BENBULL/message/205192728

Judging from the strong demand for this immuno-supportive formula product, the future earnings should be very good for HWGB going forward. So, the mystery remain as to what was the hidden agenda behind the Board to take the firm private at a meagre 0.125? Guess that's not too difficult to figure out by now...lol

Congrats to those who held on tightly to their shares...more upsides to come :-)

Its a cornered stock!
1.50 easy meat :-)

With IDSS's wings clipped further till 30th Jun, syndicates can only push it up to make money :)

1) COVID-19 Nucleic Acid Test Kit
http://www.mdeasydiagnosis.com/en/products/Molecular/2020-03-20/63.html

2) Nucleic Acid Extraction Reagent
http://www.mdeasydiagnosis.com/en/products/Molecular/2020-03-20/64.html

Wuhan Easy Diagnosis Biomedicine Co., Ltd, Located in the National Biological Industry Base in Wuhan province, China. We are a leading IVD manufacturer, specializing in development, production and sales of POCT rapid diagnostic reagents and related equipment.

We have a strong and professional R&D team, with 100,000 grade clean workshop and international leading production lines. All our products line have been gotten ISO13485：2016 , CE certification, and more than 20 parameters of POCT rapid diagnostic products with SFDA registration. Also, we are the first company making bedside, rapid and quantitative detection in whole blood in China. And our products are selling more than 20 countries. Our intelligent management system provides hospital departments at all levels detections including cardiovascular disease, kidney disease, infectious disease, endocrine and metabolic diseases, obstetrics and gynecology, and eugenics, physical examination and other comprehensive solutions.

Director selling is not a good omen :(

These new Covid-19 test kits are of high standard & very reliable. MOH"s approval shouldn't be a problem: -
"COVID-19 Nucleic Acid Test Kit and Nucleic Acid Extraction Reagent."